PATENT *IPu*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
( Case No. 04-105 (400/146) )

In the Application of:

James McSwiggen

Serial No.: 10/783,128

Filing Date: February 20, 2004

For: RNA INTERFERENCE MEDIATED  
TREATMENT OF POLYGLUTAMINE  
(POLYQ) REPEAT EXPANSION DISEASES  
USING SHORT INTERFERING NUCLEIC  
ACID (siNA)

Examiner: TBD

Group Art Unit: 1614

Confirmation No.: 2611

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**TRANSMITTAL LETTER**

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Second Supplemental Information Disclosure Statement;
- ☒ Second Supplemental Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/783,128 (Total 3 foreign patent and 3 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.


3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on August 9, 2005.

By :

*Anita J. Terpstra*  
Anita J. Terpstra  
Reg. No. 47,132

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
TELEPHONE (312) 913-0001  
FACSIMILE: (312) 913-0002



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 04-105 (400/146) )**

<b>In the Application of:</b>	)	
	)	
<b>James McSwiggen</b>	)	
	)	<b>Examiner: TBD</b>
<b>Serial No.: 10/783,128</b>	)	
	)	<b>Group Art Unit: 1614</b>
<b>Filing Date: February 20, 2004</b>	)	
	)	<b>Confirmation No.: 2611</b>
<b>For: RNA INTERFERENCE MEDIATED</b>	)	
<b>TREATMENT OF POLYGLUTAMINE</b>	)	
<b>(POLYQ) REPEAT EXPANSION DISEASES</b>	)	
<b>USING SHORT INTERFERING NUCLEIC</b>	)	
<b>ACID (siNA)</b>	)	

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents

~~P.O. Box 1450~~

Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. A partial recitation of the priority claim is as follows. This application is a continuation-in-part of U.S. Patent Application No. 10/757,803, filed January 14, 2004, which is a continuation-in-part of U.S. Patent Application No. 10/720,448, filed November 24, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/693,059, filed October 23, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/444,853, filed May 23, 2003 and a continuation-in-part of 10/652,791, filed August 29, 2003, which is a continuation of 10/422,704, filed April 24, 2003, which is a continuation of U.S. Patent Application No. 10/417,012, filed April 16, 2003. This application is also a continuation-in-part of US Patent Application No. 10/427,160, filed April 30, 2003. All of the applications recited herein are relied upon for an earlier filing date under 35 U.S.C. § 120.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

As this Information Disclosure Statement is being submitted after receipt of a foreign search report, a copy of the search report is attached herewith.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.


Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: August 9, 2005

By:

  
Anita J. Terpstra  
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

04-105  
(400/146)

10/783,128

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

James McSwiggen

**Filing Date:**

February 20, 2004

**Group:**

1614

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	03/070887	08/28/03	WO (McSwiggen et al.)				
	2.	03/070896	08/28/03	WO (McSwiggen et al.)				
	3.	03/074654	09/12/03	WO (McSwiggen et al.)				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

	4.	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	5.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
	6.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.